MA38009B1 - Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer - Google Patents

Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer

Info

Publication number
MA38009B1
MA38009B1 MA38009A MA38009A MA38009B1 MA 38009 B1 MA38009 B1 MA 38009B1 MA 38009 A MA38009 A MA 38009A MA 38009 A MA38009 A MA 38009A MA 38009 B1 MA38009 B1 MA 38009B1
Authority
MA
Morocco
Prior art keywords
compounds
cancer
treatment
prophylaxis
inhibitory activity
Prior art date
Application number
MA38009A
Other languages
English (en)
Other versions
MA38009A1 (fr
Inventor
Joan Heather Hogg
Robert Francis Kester
Weiling Liang
Weiya Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38009A1 publication Critical patent/MA38009A1/fr
Publication of MA38009B1 publication Critical patent/MA38009B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)

Abstract

L'invention concerne des composés de formule (i), ou leurs sels pharmaceutiquement acceptables, dans laquelle w, y, z, r1, r2, r3 et r4 sont tels que décrits dans la présente demande, et des procédés d'utilisation des composés dans le traitement du cancer.
MA38009A 2012-10-11 2013-10-08 Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer MA38009B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712305P 2012-10-11 2012-10-11
PCT/EP2013/070881 WO2014056871A1 (fr) 2012-10-11 2013-10-08 Azaindolines

Publications (2)

Publication Number Publication Date
MA38009A1 MA38009A1 (fr) 2018-02-28
MA38009B1 true MA38009B1 (fr) 2018-09-28

Family

ID=49304982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38009A MA38009B1 (fr) 2012-10-11 2013-10-08 Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer

Country Status (18)

Country Link
US (1) US9309248B2 (fr)
EP (1) EP2906559B1 (fr)
JP (1) JP6333826B2 (fr)
KR (1) KR20150067182A (fr)
CN (1) CN104540825B (fr)
AU (1) AU2013328870A1 (fr)
CA (1) CA2880324A1 (fr)
CL (1) CL2015000886A1 (fr)
CR (1) CR20150148A (fr)
EA (1) EA201590656A1 (fr)
ES (1) ES2623304T3 (fr)
IL (1) IL237115A (fr)
MA (1) MA38009B1 (fr)
MX (1) MX2015004525A (fr)
PE (1) PE20150965A1 (fr)
PH (1) PH12015500399A1 (fr)
SG (1) SG11201501314TA (fr)
WO (1) WO2014056871A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016079527A1 (fr) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Polythérapie
WO2016097773A1 (fr) 2014-12-19 2016-06-23 Children's Cancer Institute Antagonistes des iap thérapeutiques pour traiter des troubles prolifératifs
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
AU2018297592B2 (en) * 2017-07-06 2021-12-16 Janssen Pharmaceutica Nv New substituted azaindoline derivatives as NIK inhibitors
US12636370B2 (en) 2019-08-08 2026-05-26 Institute For Cancer Research Combination therapy for treatment of cancer
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118985A1 (fr) * 1993-04-02 1994-10-03 Dinesh V. Patel Inhibiteurs heterocycliques de la farnesyl proteine transferase
CA2447999C (fr) * 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utilisations
BRPI0513310A (pt) * 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
AU2006271781A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8835393B2 (en) * 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
EP2493879B1 (fr) * 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Mimétiques dimères de smac
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
BR112015005627A2 (pt) * 2012-10-11 2017-08-08 Hoffmann La Roche composto, composição farmacêutica, uso de composto, método de tratamento e invenção.

Also Published As

Publication number Publication date
IL237115A (en) 2016-12-29
HK1206738A1 (en) 2016-01-15
SG11201501314TA (en) 2015-03-30
EP2906559B1 (fr) 2017-02-08
CN104540825B (zh) 2017-10-24
ES2623304T3 (es) 2017-07-10
US20150266879A1 (en) 2015-09-24
CR20150148A (es) 2015-04-30
PE20150965A1 (es) 2015-06-20
WO2014056871A1 (fr) 2014-04-17
MA38009A1 (fr) 2018-02-28
JP2015534570A (ja) 2015-12-03
CN104540825A (zh) 2015-04-22
EP2906559A1 (fr) 2015-08-19
CA2880324A1 (fr) 2014-04-17
KR20150067182A (ko) 2015-06-17
JP6333826B2 (ja) 2018-05-30
EA201590656A1 (ru) 2015-07-30
PH12015500399A1 (en) 2015-04-27
US9309248B2 (en) 2016-04-12
AU2013328870A1 (en) 2015-02-26
MX2015004525A (es) 2015-07-06
CL2015000886A1 (es) 2015-07-17

Similar Documents

Publication Publication Date Title
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA41014B1 (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
MA35184B1 (fr) Antagonistes de trpv4
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA44948A1 (fr) Inhibiteurs de bace 1
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA38240B1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA35895B1 (fr) Inhibiteurs d'iap
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique